Paper42489754
Real-world study of effectiveness and safety compared among isavuconazole, amphotericin B, and voriconazole in invasive mold disease patients.
Qiu Y and 6 others. Eur J Clin Microbiol Infect Dis, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Real-world study of effectiveness and safety compared among isavuconazole, amphotericin B, and voriconazole in invasive mold disease patients. Papers, record 42489754. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42489754
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Real-world study of effectiveness and safety compared among isavuconazole, amphotericin B, and voriconazole in invasive mold disease patients.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| NSFC82202544 & NSFC82270007 | the National Natural Science Foundation of China | PubMed | ||
| 2023ZD0506200 & 2023ZD0506204 | the National Key Research and Development Program of China | PubMed | ||
| 2021GXNSFBA220064 | Natural Science Foundation of Guangxi Province | PubMed | ||
| 202201020537 | the Science and Technology Program of Guangzhou | PubMed | ||
| No. 2023M730801 | the China Postdoctoral Science Foundation | PubMed | ||
| SKLRD- Z-202019 | the State Key Laboratory of Respiratory Diseases | PubMed |
Source PubMed
References23
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28355466 | Invasive mould infections in the ICU setting: complexities and solutions. | J Antimicrob Chemother | 2017 | https://conductscience.org/library/papers/28355466 | PubMed |
| 2 | 28355467 | New pharmacological opportunities for the treatment of invasive mould diseases. | J Antimicrob Chemother | 2017 | https://conductscience.org/library/papers/28355467 | PubMed |
| 3 | 23729001 | Amphotericin B formulations: a comparative review of efficacy and toxicity. | Drugs | 2013 | https://conductscience.org/library/papers/23729001 | PubMed |
| 4 | 33333012 | Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. | Lancet Infect Dis | 2021 | https://conductscience.org/library/papers/33333012 | PubMed |
| 5 | 31699664 | Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. | Lancet Infect Dis | 2019 | https://conductscience.org/library/papers/31699664 | PubMed |
| 6 | 34882852 | Incidence, risk factors and mortality of invasive pulmonary aspergillosis in patients with influenza: A systematic review and meta-analysis. | Mycoses | 2022 | https://conductscience.org/library/papers/34882852 | PubMed |
| 7 | 11801575 | Amphotericin B: spectrum and resistance. | J Antimicrob Chemother | 2002 | https://conductscience.org/library/papers/11801575 | PubMed |
| 8 | 24548001 | ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. | Clin Microbiol Infect | 2014 | https://conductscience.org/library/papers/24548001 | PubMed |
| 9 | 26179012 | Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. | Clin Infect Dis | 2015 | https://conductscience.org/library/papers/26179012 | PubMed |
| 10 | 31802125 | Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. | Clin Infect Dis | 2020 | https://conductscience.org/library/papers/31802125 | PubMed |
| 11 | 12167683 | Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. | N Engl J Med | 2002 | https://conductscience.org/library/papers/12167683 | PubMed |
| 12 | 35171022 | Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study). | Microbiol Spectr | 2022 | https://conductscience.org/library/papers/35171022 | PubMed |
| 13 | 37300337 | A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections. | Mycoses | 2023 | https://conductscience.org/library/papers/37300337 | PubMed |
| 14 | 36530445 | Clinical research advances of isavuconazole in the treatment of invasive fungal diseases. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/36530445 | PubMed |
| 15 | 12823944 | Antifungal agents: mechanisms of action. | Trends Microbiol | 2003 | https://conductscience.org/library/papers/12823944 | PubMed |
| 16 | 35320642 | Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35320642 | PubMed |
| 17 | 31279853 | Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population. | Int J Antimicrob Agents | 2019 | https://conductscience.org/library/papers/31279853 | PubMed |
| 18 | 29725999 | Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole. | Clin Pharmacokinet | 2018 | https://conductscience.org/library/papers/29725999 | PubMed |
| 19 | 30306415 | Isavuconazole Kinetic Exploration for Clinical Practice. | Drugs R D | 2018 | https://conductscience.org/library/papers/30306415 | PubMed |
| 20 | 29570857 | Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. | Mycoses | 2018 | https://conductscience.org/library/papers/29570857 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42489754
GET https://conductscience.org/api/papers/v1/42489754/references?page=2